Pharma Focus America

Avenacy Launches Isoproterenol Hydrochloride Injection, USP in the U.S.

Tuesday, May 21, 2024

Avenacy, a specialized pharmaceutical company focused on supplying critical injectable medications, has announced the launch of Isoproterenol Hydrochloride Injection, USP in the United States. This medication serves as a therapeutic generic equivalent for ISUPREL®, as approved by the U.S. Food and Drug Administration.

Isoproterenol Hydrochloride Injection, USP is intended for various medical purposes, including treating mild or transient heart block episodes not requiring electric shock or pacemaker therapy, serious heart block episodes and Adams-Stokes attacks (except those caused by ventricular tachycardia or fibrillation), cardiac arrest prior to electric shock or pacemaker therapy availability, and bronchospasm during anesthesia. It also serves as an adjunct therapy in conditions such as hypovolemic and septic shock, low cardiac output states, congestive heart failure, and cardiogenic shock.

Avenacy's Isoproterenol Hydrochloride Injection, USP is offered in 0.2 mg/mL and 1 mg/5 mL 10-pack single-dose vials. The company emphasizes patient safety and care by providing highly differentiated packaging and labeling to facilitate accurate medication selection.

Shipping of Isoproterenol Hydrochloride Injection, USP to wholesale partners will commence this week. Avenacy relies on a global network of development and contract manufacturing partners that comply with cGMP standards and have undergone successful FDA inspections.

Isoproterenol Hydrochloride Injection, USP achieved U.S. sales of approximately $26 million for the twelve months ending in June 2023.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024